ArticleThoracic cancer2026
Anatomical Sublobar Resection for Multi-Intersegmental Pulmonary Nodules.
Article in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anatomical Sublobar Resection for Multi-Intersegmental Pulmonary Nodules.Thoracic cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAnatomical sublobar resection (ASR) is non-inferior to lobectomy for peripheral small-sized lung cancer. However, for nodules located in complex locations, ASR is usually challenging. This study aimed to compare the outcomes of ASR and lobectomy for multi-intersegmental pulmonary nodules.
methodsPatients with pulmonary nodules (≤ 2 cm) who underwent ASR or lobectomy between 2012 and 2023 were retrospectively screened. The 3D multiplanar reconstruction software was used to determine the precise tumor localization. Demographic, radiomic, histopathologic, and perioperative characteristics between ASR and lobectomy were compared. The log rank test was adopted for prognostic evaluation. Propensity score-matching (PSM) analysis was conducted to yield matched patients.
resultsIn total, 93 patients undergoing ASR and 118 subjects undergoing lobectomy were included. Patients with ASR were younger and had a smaller tumor size, fewer solid nodules, and more central nodules than those with lobectomy. ASR achieved a median surgical margin of 2.0 cm, removed fewer lymph nodes, and preserved seven more subsegments than lobectomy (5 vs. 12, p < 0.001), without increasing air leak or postoperative hospital stay. During a median follow-up of 32 months, four patients in the lobectomy group encountered tumor recurrence, whereas no recurrence occurred in the ASR group. The 5-year recurrence-free survival (RFS) after lobectomy and ASR was 95.4% and 100%, respectively. After PSM, 34 matched patients remained in each group, and the RFS was 100% in both groups.
conclusionsASR is feasible for multi-intersegmental nodules and can preserve more pulmonary parenchyma with no compromise in perioperative and oncological outcomes compared to lobectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.